论文部分内容阅读
目的:探讨柔肝化纤合剂联合阿德福韦酯胶囊治疗气滞血瘀型乙型肝炎肝纤维化的临床疗效。方法:治疗组82例采用院内制剂柔肝化纤合剂联合阿德福韦酯胶囊治疗;对照组82例采用阿德福韦酯胶囊联合其他常规保肝药物。12个月后观察两组患者超声指标及血生化指标。结果:治疗后,治疗组患者Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、脯氨酸肽酶(PLD)、Ⅳ型胶原(Ⅳ-C)、层粘连蛋白(LN)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、白蛋白(ALB)、肝门静脉(hpv)和脾静脉(sv)内径和脾脏的厚度均较对照组降低,差异有统计学意义。结论:柔肝化纤合剂联合阿德福韦酯胶囊能有效改善气滞血瘀型乙型肝炎肝纤维化的肝功能、肝纤维化及超声学指标,具有治疗和逆转肝纤维化的作用。
Objective: To investigate the clinical efficacy of Rougan Huaxian Mixture combined with adefovir dipivoxil capsule in treating hepatitis B liver fibrosis with qi stagnation and blood stasis syndrome. Methods: 82 cases of the treatment group were treated with the intra-hospital preparation of Rougan chemical fiber combined with adefovir dipivoxil capsules. The control group of 82 cases were treated with adefovir dipivoxil capsules and other conventional hepatoprotective drugs. Twelve months later, the ultrasound and blood biochemical parameters of two groups were observed. Results: After treatment, the levels of PC Ⅲ, HA, PLD, Ⅳ-C, LN, ALT, AST, TBIL, ALB, hepatic portal vein (hpv), splenic vein (sv) and spleen Lower than the control group, the difference was statistically significant. Conclusion: Rougan Huaxian Mixture combined with adefovir dipivoxil capsule can effectively improve hepatic function, hepatic fibrosis and ultrasound indexes of hepatitis B with hepatic fibrosis in qi stagnation and blood stasis syndrome, and has the effect of treating and reversing hepatic fibrosis.